CRVS logo

Corvus Pharmaceuticals (CRVS) EBITDA

Annual EBITDA

-$23.26 M
+$8.94 M+27.77%

December 31, 2023

Summary

Performance

1-Year Change

+27.77%

3-Year Change

+46.08%

5-Year Change

+51.93%

15-Year Change

+58.23%

CRVS EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

49.32%
CRVS annual EBITDA is higher than 49.32% of companies in Healthcare sector

High & Low

All-time High

-$13.62 M

3-Year Low

-$38.17 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
CRVS previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Mar 19, 2025
CRVS next annual earnings announcement is scheduled for Mar 19, 2025

OtherCRVSprofitabilitymetrics:

Annual Revenue

-
CRVS annual revenue value is unknown

Annual Net Income

-$27.03 M
CRVS annual net profit is -$27.03 million

Annual EBIT

-$23.41 M
CRVS annual earnings before interest & taxes is -$23.41 million

Annual EPS

-$0.56
CRVS annual earnings per share is -$0.56

Quarterly EBITDA

-$7.23 M
-$1.32 M-22.32%

September 30, 2024

Summary

Performance

3-Month Change

-22.32%

1-Year Change

-30.81%

3-Year Change

-29.83%

5-Year Change

-29.83%

CRVS Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

41.53%
CRVS quarterly EBITDA is higher than 41.53% of companies in Healthcare sector

High & Low

All-time High

$11.55 M
CRVS quarterly EBITDA is currently -162.62% below its historical high of $11.55 million

3-Year Low

-$12.38 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
CRVS previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Mar 19, 2025
CRVS next earnings announcement is scheduled for Mar 19, 2025

OtherCRVSprofitabilitymetrics:

Quarterly Revenue

-
CRVS quarterly revenue value is unknown

Quarterly Net Income

-$40.22 M
CRVS quarterly net profit is -$40.22 million

Quarterly EBIT

-$7.25 M
CRVS quarterly earnings before interest & taxes is -$7.25 million

Quarterly EPS

-$0.60
CRVS quarterly earnings per share is -$0.60

TTM EBITDA

-$25.00 M
-$1.70 M-7.31%

September 30, 2024

Summary

Performance

3-Month Change

-7.31%

1-Year Change

-7.74%

3-Year Change

+22.35%

5-Year Change

+22.35%

CRVS TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

45.97%
CRVS TTM EBITDA is higher than 45.97% of companies in Healthcare sector

High & Low

All-time High

$3.98 M
CRVS TTM EBITDA is currently -728.48% below its historical high of $3.98 million

3-Year Low

-$37.61 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
CRVS previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Mar 19, 2025
CRVS next earnings announcement is scheduled for Mar 19, 2025

OtherCRVSprofitabilitymetrics:

TTM Revenue

-
CRVS TTM revenue value is unknown

TTM Net Income

-$56.83 M
CRVS TTM net profit is -$56.83 million

TTM EBIT

-$25.09 M
CRVS TTM earnings before interest & taxes is -$25.09 million

TTM EPS

-$0.92
CRVS TTM earnings per share is -$0.92

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

-$23.26 M
CRVS annual EBITDA is -$23.26 million

Annual Net Income

-$27.03 M
CRVS annual net profit is -$27.03 million

Annual Interest Expense

-
CRVS annual interest expense value is unknown

Annual Income Tax

-
CRVS annual income tax value is unknown

Annual D&A

$151.00 K
CRVS annual depreciation & amortization is $151.00 thousand

CRVS EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+27.8%-30.8%-7.7%
3 y3 years+46.1%-29.8%+22.4%
5 y5 years+51.9%-29.8%+22.4%

CRVS EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+39.1%-59.4%+41.6%-8.8%+33.5%
5 y5-yearat high+51.7%-59.4%+44.7%-8.8%+49.1%
alltimeall time-70.7%+58.2%-162.6%+54.8%-728.5%+55.1%

Corvus Pharmaceuticals EBITDA History

DateAnnualQuarterlyTTM
Sep 2024
-
-$7.23 M(+22.3%)
-$25.00 M(+7.3%)
Jun 2024
-
-$5.91 M(-5.1%)
-$23.30 M(+1.4%)
Mar 2024
-
-$6.23 M(+10.8%)
-$22.97 M(-1.2%)
Dec 2023
-$23.26 M(-27.8%)
-$5.62 M(+1.7%)
-$23.26 M(+0.2%)
Sep 2023
-
-$5.53 M(-1.0%)
-$23.20 M(-22.8%)
Jun 2023
-
-$5.59 M(-14.3%)
-$30.05 M(-4.3%)
Mar 2023
-
-$6.52 M(+17.0%)
-$31.39 M(-2.5%)
Dec 2022
-$32.20 M(-15.6%)
-$5.57 M(-55.0%)
-$32.20 M(+3.3%)
Sep 2022
-
-$12.38 M(+78.9%)
-$31.16 M(+6.2%)
Jun 2022
-
-$6.92 M(-5.5%)
-$29.34 M(-12.6%)
Mar 2022
-
-$7.33 M(+61.4%)
-$33.59 M(-10.7%)
Dec 2021
-$38.17 M(-11.5%)
-$4.54 M(-57.0%)
-$37.61 M(-12.1%)
Sep 2021
-
-$10.55 M(-5.5%)
-$42.80 M(+2.0%)
Jun 2021
-
-$11.17 M(-1.6%)
-$41.95 M(+1.4%)
Mar 2021
-
-$11.35 M(+16.5%)
-$41.39 M(-4.0%)
Dec 2020
-$43.13 M(-10.4%)
-$9.74 M(+0.4%)
-$43.13 M(-3.4%)
Sep 2020
-
-$9.70 M(-8.6%)
-$44.65 M(-3.5%)
Jun 2020
-
-$10.61 M(-18.9%)
-$46.27 M(-5.7%)
Mar 2020
-
-$13.09 M(+16.3%)
-$49.08 M(+2.0%)
DateAnnualQuarterlyTTM
Dec 2019
-$48.11 M(-0.5%)
-$11.26 M(-0.6%)
-$48.11 M(+0.6%)
Sep 2019
-
-$11.33 M(-15.5%)
-$47.85 M(+0.9%)
Jun 2019
-
-$13.41 M(+10.7%)
-$47.44 M(+3.0%)
Mar 2019
-
-$12.12 M(+10.3%)
-$46.07 M(-4.8%)
Dec 2018
-$48.38 M(-13.1%)
-$10.99 M(+0.6%)
-$48.38 M(-2.0%)
Sep 2018
-
-$10.92 M(-9.3%)
-$49.35 M(-3.5%)
Jun 2018
-
-$12.04 M(-16.5%)
-$51.17 M(-5.4%)
Mar 2018
-
-$14.43 M(+20.5%)
-$54.09 M(-2.9%)
Dec 2017
-$55.68 M(+53.0%)
-$11.97 M(-6.0%)
-$55.68 M(+1.7%)
Sep 2017
-
-$12.73 M(-14.9%)
-$54.78 M(+4.6%)
Jun 2017
-
-$14.97 M(-6.5%)
-$52.36 M(+13.6%)
Mar 2017
-
-$16.01 M(+44.7%)
-$46.08 M(+26.6%)
Dec 2016
-$36.38 M(+167.1%)
-$11.06 M(+7.3%)
-$36.38 M(+164.3%)
Sep 2016
-
-$10.32 M(+18.8%)
-$13.77 M(+111.3%)
Jun 2016
-
-$8.68 M(+37.4%)
-$6.51 M(+4948.8%)
Mar 2016
-
-$6.32 M(-154.7%)
-$129.00 K(-103.2%)
Dec 2015
-$13.62 M
$11.55 M(-476.9%)
$3.98 M(-152.5%)
Sep 2015
-
-$3.06 M(+33.4%)
-$7.58 M(+68.0%)
Jun 2015
-
-$2.30 M(+3.8%)
-$4.51 M(+103.8%)
Mar 2015
-
-$2.21 M
-$2.21 M

FAQ

  • What is Corvus Pharmaceuticals annual EBITDA?
  • What is the all time high annual EBITDA for Corvus Pharmaceuticals?
  • What is Corvus Pharmaceuticals annual EBITDA year-on-year change?
  • What is Corvus Pharmaceuticals quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Corvus Pharmaceuticals?
  • What is Corvus Pharmaceuticals quarterly EBITDA year-on-year change?
  • What is Corvus Pharmaceuticals TTM EBITDA?
  • What is the all time high TTM EBITDA for Corvus Pharmaceuticals?
  • What is Corvus Pharmaceuticals TTM EBITDA year-on-year change?

What is Corvus Pharmaceuticals annual EBITDA?

The current annual EBITDA of CRVS is -$23.26 M

What is the all time high annual EBITDA for Corvus Pharmaceuticals?

Corvus Pharmaceuticals all-time high annual EBITDA is -$13.62 M

What is Corvus Pharmaceuticals annual EBITDA year-on-year change?

Over the past year, CRVS annual EBITDA has changed by +$8.94 M (+27.77%)

What is Corvus Pharmaceuticals quarterly EBITDA?

The current quarterly EBITDA of CRVS is -$7.23 M

What is the all time high quarterly EBITDA for Corvus Pharmaceuticals?

Corvus Pharmaceuticals all-time high quarterly EBITDA is $11.55 M

What is Corvus Pharmaceuticals quarterly EBITDA year-on-year change?

Over the past year, CRVS quarterly EBITDA has changed by -$1.70 M (-30.81%)

What is Corvus Pharmaceuticals TTM EBITDA?

The current TTM EBITDA of CRVS is -$25.00 M

What is the all time high TTM EBITDA for Corvus Pharmaceuticals?

Corvus Pharmaceuticals all-time high TTM EBITDA is $3.98 M

What is Corvus Pharmaceuticals TTM EBITDA year-on-year change?

Over the past year, CRVS TTM EBITDA has changed by -$1.80 M (-7.74%)